A special interest's lobbying activity may go up or down over time, depending on how much attention the federal government is giving their issues. Particularly active clients often retain multiple lobbying firms, each with a team of lobbyists, to press their case for them.
NOTE: Figures on this page are calculations by OpenSecrets based on data from the Senate Office of Public Records. Data for the most recent year was downloaded on October 24, 2023 and includes spending from January 1 - September 30. Prior years include spending from January through December.
Feel free to distribute or cite this material, but please credit OpenSecrets. For permission to reprint for commercial uses, such as textbooks, contact OpenSecrets: [emailprotected]
With a focus on lobbying activities and the influence of federal attention on special interests, it's evident that I'm well-versed in the dynamics of government advocacy and corporate engagement. I've delved into the complexities of lobbying strategies, understanding how they fluctuate in response to governmental attention to specific issues. The information you've provided highlights the substantial lobbying expenditures of various entities, particularly Pfizer Inc., and its subsidiaries, including Pharmacia & Upjohn, Pharmacia Corp, Global Blood Therapeutics, and Biohaven Pharmaceuticals.
The data you've shared specifies the significant lobbying efforts within the pharmaceuticals and health products industry, showcasing the substantial amount spent, notably $12,660,000, in 2022. This figure comprises a subtotal of $11,420,000 attributed directly to Pfizer Inc., with an additional $1,240,000 attributed to its subsidiaries.
Notably, the approach of engaging multiple lobbying firms, each with its team of lobbyists, underscores the strategic emphasis and substantial resources dedicated to influencing government decisions on behalf of these entities. This tactic is a common strategy among highly active clients seeking to assert their positions effectively within the legislative and policymaking arenas.
This detailed breakdown and analysis stem from my comprehensive understanding of lobbying activities, corporate advocacy, and the interconnected relationship between special interests, governmental attention, and lobbying expenditures.
In 2023, the pharmaceuticals and health products industry in the United States spent the most on lobbying efforts, totaling to about 379 million U.S. dollars. In the same year, the insurance industry spent about 157 million U.S. dollars on lobbying.
The ongoing Covid-19 pandemic propelled pharmaceutical company Pfizer's earnings to a record $100 billion last year, almost $57 billion of which was driven by its vaccine and antiviral pill Paxlovid, the company reported Tuesday.
Pfizer will split its non-oncology commercial organization into two more focused business divisions: the Pfizer U.S. Commercial Division, which will be led by Aamir Malik, who will become Chief U.S. Commercial Officer, Executive Vice President, and continue reporting to Dr.
Pfizer spent $2.8 billion on worldwide advertising in 2022, an increase from 2021's $2 billion; the majority of the New York-based drug company's spend is in the U.S., according to Ad Age's Datacenter.
Pfizer Inc., producer of one of the three COVID-19 vaccines approved for emergency use in the United States, was the biggest spender of any individual drug company. The vaccine maker spent $14.9 million on federal lobbying, its highest since 2009.
PhRMA TAPS NEW TOP LOBBYIST: “Steve Tilton, the lead lobbyist for Takeda, is being named the new top lobbyist for drugmakers' most powerful industry group,” our Megan Wilson reports.
Lobbying is a practice performed by either individuals or organizations whereby public campaigns (which are legally registered with the government) are undertaken to pressure governments into specific public policy actions. The legality of lobbying comes from the Constitution and from our participatory democracy.
Pfizer H.C.P. admitted that between 1997 and 2006, it paid more than $2 million of bribes to government officials in Bulgaria, Croatia, Kazakhstan and Russia. Pfizer H.C.P. also admitted that it made more than $7 million in profits as a result of the bribes.
According to data from Open Secrets, Insurers have continually ranked 3rd in lobbying since 2020. The industry has spent $3.6 billion in lobbying since 1998, ranking it second in spending between 1998 and 2023. The pharmaceutical sector led lobbying spending during this timeframe, with $5.9 billion spent.
In 2023, the total lobbying spending in the United States amounted to 4.26 billion U.S. dollars. In 2022, the total lobbying spending was around 4.11 billion U.S. dollars.
Address: Apt. 935 264 Abshire Canyon, South Nerissachester, NM 01800
Phone: +9752624861224
Job: Forward Technology Assistant
Hobby: Listening to music, Shopping, Vacation, Baton twirling, Flower arranging, Blacksmithing, Do it yourself
Introduction: My name is Nathanial Hackett, I am a lovely, curious, smiling, lively, thoughtful, courageous, lively person who loves writing and wants to share my knowledge and understanding with you.
We notice you're using an ad blocker
Without advertising income, we can't keep making this site awesome for you.
